Table 3. Treatments after disease progression.
| Group | ||
|---|---|---|
| PCI (N = 60) | non-PCI (N = 20) | |
| Disease recurrence*1 | 28 (46.7%) | 10 (50%) |
| Second-line chemotherapy | 27*2 | 7 |
| Single agents | 14 | 4 |
| Platinum-based doublet | 13 | 3 |
| Third-line chemotherapy | 19 | 6 |
| Single agents | 14 | 5 |
| Platinum-based doublet | 5 | 1 |
| Fourth-line chemotherapy | 11 | 5 |
| Single agents | 10 | 4 |
| Platinum-based doublet | 1 | 1 |
| Brain metastases recurrences | 17 (28.3%) | 8 (40%) |
| Radiation therapy for BM recurrences | 11 | 6 |
| WBRT | 2 | 6 |
| WBRT + SRT | 1 | 0 |
| WBRT + SRS | 1 | 0 |
| SRT | 4 | 0 |
| SRS | 3 | 0 |
| Chemotherapy for BM recurrences | 4 | 1 |
| Untreated | 1 | 0 |
| Unknown | 1 | 1 |
*1Brain metastases recurrences are included in disease progression.
*21 patient out of the 28 who have disease recurrences received thoracic radiation therapy for local recurrence.
Abbreviation: PCI, prophylactic cranial irradiation; BM, brain metastases; WBRT, whole brain radiation therapy; SRT, Stereotactic radiotherapy; SRS, Stereotactic radiosurgery.